Bicycle Therapeutics Plc (BCYC): who owns it and who trades it
As of Nov 16, 2026, BCYC insiders reported 48 open-market sales worth $522K and no purchases in the last 12 months, with 13% of the sale value made under pre-set 10b5-1 plans. The largest seller was Kevin Lee (CEO), with $239K. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Bicycle Therapeutics
From the latest filingsOverall: more selling than buying. Insiders and famous investors mostly sold. Funds mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns BCYC
104 funds and institutions reported BCYC shares worth $159M at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Baker Bros. Advisors LP with 36.2%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Baker Bros. Advisors LP | 10.89M | 36.23% | $46.2M | No change |
| Fcpm III Services B.v. | 3.47M | 11.54% | $14.7M | No change |
| Armistice Capital, LLC | 3.40M | 11.31% | $14.4M | No change |
| Long Focus Capital Management, LLC | 3.31M | 11.02% | $14M | No change |
| Acadian Asset Management LLC | 1.97M | 6.55% | $8.3M | No change |
| Renaissance Technologies LLC | 1.53M | 5.10% | $6.5M | +57% |
| GSK plc | 1.53M | 5.09% | $6.5M | No change |
| T. Rowe Price Associates | 902,150 | 3.00% | $3.8M | -12% |
| Marshall Wace, LLP | 797,940 | 2.66% | $3.4M | +111% |
| Qube Research & Technologies Ltd | 775,567 | 2.58% | $3.3M | +151% |
| Morgan Stanley | 667,269 | 2.22% | $2.8M | +8% |
| Schroder Investment Management Group | 615,833 | 2.05% | $2.6M | No change |
| Citadel Advisors LLC | 554,225 | 1.84% | $2.3M | +47% |
| Millennium Management LLC | 553,967 | 1.84% | $2.3M | +95% |
| Peapod Lane Capital LLC | 537,978 | 1.79% | $2.3M | +344% |
| Diadema Partners LP | 462,724 | 1.54% | $2M | -3% |
| Two Sigma Investments, LP | 434,577 | 1.45% | $1.8M | +164% |
| Jane Street Group, LLC | 392,163 | 1.31% | $1.7M | +80% |
| Flax Pond Capital, LLC | 376,222 | 1.25% | $1.7M | +114% |
| Birchview Capital, LP | 313,616 | 1.04% | $1.3M | -32% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, BCYC insiders reported $0 of open-market purchases and $522K of sales. 13% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 5, 2026 | Jennifer Scott Perry | Chief Operating Officer | Sale plan | 30 | $3.57 | $107 | Form 4 |
| Oct 5, 2026 | Michael Skynner | CHIEF SCIENTIFIC OFFICER | Sale | 503 | $3.57 | $1.8K | Form 4 |
| Oct 5, 2026 | Kevin Lee | CEO | Sale | 1,638 | $3.57 | $5.8K | Form 4 |
| Oct 5, 2026 | Travis Alvin Thompson | CFO | Sale | 79 | $3.57 | $282 | Form 4 |
| Oct 5, 2026 | Michael Charles Ferguson Hannay | CHIEF PROD & SUPPLY CHAI | Sale | 242 | $3.57 | $864 | Form 4 |
| Oct 5, 2026 | Jennifer Scott Perry | Chief Operating Officer | Sale plan | 80 | $3.56 | $285 | Form 4 |
| Oct 5, 2026 | Jennifer Scott Perry | Chief Operating Officer | Sale plan | 326 | $3.78 | $1.2K | Form 4 |
| Oct 2, 2026 | Michael Skynner | CHIEF SCIENTIFIC OFFICER | Sale | 1,942 | $3.47 | $6.7K | Form 4 |
| Oct 2, 2026 | Kevin Lee | CEO | Sale | 6,167 | $3.47 | $21.4K | Form 4 |
| Oct 2, 2026 | Travis Alvin Thompson | CFO | Sale | 893 | $3.47 | $3.1K | Form 4 |
| Oct 2, 2026 | Michael Charles Ferguson Hannay | CHIEF PROD & SUPPLY CHAI | Sale | 1,572 | $3.47 | $5.5K | Form 4 |
| Oct 2, 2026 | Robert Charles Swanton | Director | Sale | 3,431 | $3.47 | $11.9K | Form 4 |
| Oct 2, 2026 | Jennifer Scott Perry | Chief Operating Officer | Sale plan | 1,094 | $3.47 | $3.8K | Form 4 |
| Jul 6, 2026 | Jennifer Scott Perry | Chief Operating Officer | Sale plan | 333 | $4.34 | $1.4K | Form 4 |
| Jul 6, 2026 | Jennifer Scott Perry | Chief Operating Officer | Sale plan | 43 | $4.31 | $185 | Form 4 |
| Jul 6, 2026 | Michael Skynner | CHIEF SCIENTIFIC OFFICER | Sale | 532 | $4.31 | $2.3K | Form 4 |
| Jul 6, 2026 | Kevin Lee | CEO | Sale | 1,737 | $4.31 | $7.5K | Form 4 |
| Jul 6, 2026 | Michael Charles Ferguson Hannay | CHIEF PROD & SUPPLY CHAI | Sale | 255 | $4.31 | $1.1K | Form 4 |
| Jul 6, 2026 | Travis Alvin Thompson | CFO | Sale | 104 | $4.31 | $448 | Form 4 |
| Jul 2, 2026 | Jennifer Scott Perry | Chief Operating Officer | Sale plan | 1,036 | $4.27 | $4.4K | Form 4 |
| Jul 2, 2026 | Michael Skynner | CHIEF SCIENTIFIC OFFICER | Sale | 1,859 | $4.27 | $7.9K | Form 4 |
| Jul 2, 2026 | Kevin Lee | CEO | Sale | 5,905 | $4.27 | $25.2K | Form 4 |
| Jul 2, 2026 | Michael Charles Ferguson Hannay | CHIEF PROD & SUPPLY CHAI | Sale | 1,506 | $4.27 | $6.4K | Form 4 |
| Jul 2, 2026 | Travis Alvin Thompson | CFO | Sale | 819 | $4.27 | $3.5K | Form 4 |
| Apr 6, 2026 | Michael Charles Ferguson Hannay | CHIEF PROD & SUPPLY CHAI | Sale | 251 | $5.05 | $1.3K | Form 4 |
| Apr 6, 2026 | Travis Alvin Thompson | CFO | Sale | 102 | $5.05 | $515 | Form 4 |
| Apr 6, 2026 | Jennifer Scott Perry | Chief Operating Officer | Sale plan | 37 | $5.05 | $187 | Form 4 |
| Apr 6, 2026 | Jennifer Scott Perry | Chief Operating Officer | Sale plan | 333 | $5.04 | $1.7K | Form 4 |
| Apr 6, 2026 | Kevin Lee | CEO | Sale | 1,716 | $5.05 | $8.7K | Form 4 |
| Apr 6, 2026 | Michael Skynner | CHIEF SCIENTIFIC OFFICER | Sale | 525 | $5.05 | $2.7K | Form 4 |
| Apr 2, 2026 | Michael Charles Ferguson Hannay | CHIEF PROD & SUPPLY CHAI | Sale | 1,521 | $4.91 | $7.5K | Form 4 |
| Apr 2, 2026 | Travis Alvin Thompson | CFO | Sale | 799 | $4.91 | $3.9K | Form 4 |
| Apr 2, 2026 | Jennifer Scott Perry | Chief Operating Officer | Sale plan | 1,038 | $4.91 | $5.1K | Form 4 |
| Apr 2, 2026 | Kevin Lee | CEO | Sale | 5,967 | $4.91 | $29.3K | Form 4 |
| Apr 2, 2026 | Michael Skynner | CHIEF SCIENTIFIC OFFICER | Sale | 1,879 | $4.91 | $9.2K | Form 4 |
| Jan 5, 2026 | Travis Alvin Thompson | CHIEF ACCOUNTING OFFICER | Sale | 1,115 | $6.45 | $7.2K | Form 4 |
| Jan 5, 2026 | Michael Skynner | CHIEF TECHNOLOGY OFFICER | Sale | 3,266 | $6.46 | $21.1K | Form 4 |
| Jan 5, 2026 | Michael Charles Ferguson Hannay | CHIEF PROD & SUPPLY CHAI | Sale | 2,367 | $6.45 | $15.3K | Form 4 |
| Jan 5, 2026 | Alistair Milnes | CHIEF OPERATING OFFICER | Sale | 3,416 | $6.46 | $22.1K | Form 4 |
| Jan 5, 2026 | Alethia Young | CFO | Sale plan | 1,878 | $6.54 | $12.3K | Form 4 |
| Jan 5, 2026 | Alethia Young | CFO | Sale plan | 2,456 | $6.45 | $15.8K | Form 4 |
| Jan 5, 2026 | Kevin Lee | CEO | Sale | 10,989 | $6.46 | $71K | Form 4 |
| Jan 2, 2026 | Travis Alvin Thompson | CHIEF ACCOUNTING OFFICER | Sale | 1,317 | $6.80 | $9K | Form 4 |
| Jan 2, 2026 | Michael Skynner | CHIEF TECHNOLOGY OFFICER | Sale | 3,045 | $6.80 | $20.7K | Form 4 |
| Jan 2, 2026 | Michael Charles Ferguson Hannay | CHIEF PROD & SUPPLY CHAI | Sale | 2,827 | $6.80 | $19.2K | Form 4 |
| Jan 2, 2026 | Alistair Milnes | CHIEF OPERATING OFFICER | Sale | 3,244 | $6.80 | $22.1K | Form 4 |
| Jan 2, 2026 | Alethia Young | CFO | Sale plan | 3,289 | $6.80 | $22.4K | Form 4 |
| Jan 2, 2026 | Kevin Lee | CEO | Sale | 10,325 | $6.80 | $70.2K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Kevin Lee | CHIEF EXECUTIVE OFFICER, Director | – | $239K | Oct 5, 2026 |
| Michael Skynner | CHIEF TECHNOLOGY OFFICER | – | $72.4K | Oct 5, 2026 |
| Michael Charles Ferguson Hannay | CHIEF PROD & SUPPLY CHAIN OFF | – | $57.1K | Oct 5, 2026 |
| Alethia Young | Chief Financial Officer | – | $50.5K | Jan 5, 2026 |
| Alistair Milnes | CHIEF OPERATING OFFICER | – | $44.1K | Jan 5, 2026 |
| Travis Alvin Thompson | CHIEF ACCOUNTING OFFICER | – | $27.9K | Oct 5, 2026 |
| Jennifer Scott Perry | Chief Operating Officer | – | $18.4K | Oct 5, 2026 |
| Robert Charles Swanton | Director | – | $11.9K | Oct 2, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
BCYC short interest
3.86M BCYC shares are sold short. Over the last 12 reports the number of shares short went up 43%.
As of Oct 30, 2026, 3.86M BCYC shares were sold short, up 11.7% from the report before. At the average daily volume of 460,266 shares, buying them all back would take about 8.4 trading days (days to cover).
Shares short
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 3.86M | – | +12% | 460,266 | 8.4 |
| Oct 15, 2026 | 3.45M | – | +5% | 554,332 | 6.2 |
| Sep 30, 2026 | 3.30M | – | -1% | 378,570 | 8.7 |
| Sep 15, 2026 | 3.33M | – | +2% | 499,132 | 6.7 |
| Aug 31, 2026 | 3.28M | – | +2% | 238,343 | 13.8 |
| Aug 14, 2026 | 3.22M | – | +8% | 315,919 | 10.2 |
| Jul 31, 2026 | 2.98M | – | No change | 301,853 | 9.9 |
| Jul 15, 2026 | 2.98M | – | +3% | 388,193 | 7.7 |
| Jun 30, 2026 | 2.88M | – | +2% | 606,609 | 4.8 |
| Jun 15, 2026 | 2.83M | – | -1% | 648,641 | 4.4 |
| May 29, 2026 | 2.86M | – | +6% | 264,671 | 10.8 |
| May 15, 2026 | 2.70M | – | -8% | 356,676 | 7.6 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Bicycle Therapeutics company events
Bicycle Therapeutics filed 10 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Oct 29, 2026.
- Oct 29, 2026ResultsReleased financial results. Filing
- Aug 20, 2026LeadershipCharles Swanton resigned as a Class II director of the Board of Directors of Bicycle Therapeutics plc, as a member of the Board’s committees and as a member of the Company’s Clinical Advisory Board, effective immediately. Filing
- Jul 30, 2026ResultsReleased financial results. Filing
- Jun 18, 2026VoteReported shareholder vote results. Filing
- May 21, 2026AnnouncementBicycle Therapeutics plc issued a press release announcing initial Duravelo-2 data for metastatic urothelial cancer at the 2026 American Society of Clinical Oncology Annual Meeting. Filing
- Apr 30, 2026ResultsReleased financial results. Filing
- Apr 20, 2026AnnouncementBicycle Therapeutics plc issued a press release providing updates on its nuzefatide pevedotin program and the Company’s EphA2 pipeline. Filing
- Mar 17, 2026LeadershipThe Company’s Board of Directors appointed Jennifer Perry, Pharm.D. as Chief Operating Officer, effective as of March 17, 2026. Filing
- Feb 3, 2026LeadershipDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. Filing
- Jan 12, 2026AnnouncementBicycle Therapeutics plc issued a press release announcing the Company’s recent accomplishments and outlining strategic priorities for 2026. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Bicycle Therapeutics financials
Famous investors that hold BCYC
4 of the 50 well-known investors we track reported holding BCYC in their latest 13F filing. The largest position is Jim Simons's, worth $5.6M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 1.51M | $5.6M | 0.0% | -2% |
| Israel Englander · Millennium Management | Q3 2026 | 563,057 | $2.1M | 0.0% | +2% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 369,792 | $1.4M | 0.0% | -33% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 119,392 | $439K | 0.0% | -20% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named BCYC in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Armistice Capital, LLC | 13G/A | 6.8% |
| Nov 16, 2026 | Armistice Capital, LLC | 13G/A | 6.8% |
Questions about Bicycle Therapeutics Plc (BCYC) stock
Who owns the most BCYC stock?
The largest reported owner of Bicycle Therapeutics Plc (BCYC) is Baker Bros. Advisors LP, with 36.2% of the company. In total, 104 funds and institutions reported holding BCYC at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are BCYC insiders buying or selling?
In the last 12 months, BCYC insiders reported no open-market purchases and 48 sales worth $522K. The latest trade was on Oct 5, 2026. See every trade.
What is the short interest in BCYC?
As of Oct 30, 2026, 3.86M BCYC shares were sold short, up 11.7% from the report before. At the average daily volume of 460,266 shares, buying them all back would take about 8.4 trading days (days to cover). See the history.
Which famous investors hold BCYC?
4 of the 50 well-known investors we track reported BCYC in their latest 13F filing, including Jim Simons, Israel Englander, Ken Griffin. The largest position is worth $5.6M. See all holders.
Executive pay
Bicycle Therapeutics's chief executive was paid a total of $6.3M for the year ended Dec 31, 2025, up 31% from $4.9M the year before. In the last 12 months, Bicycle Therapeutics's executives and directors bought no stock on the open market and sold $522K.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.